Devlin Jodi
Known title: PRESIDENT, COMMERC. OPERATIONSCIK: 0001992151
Associated companies
Transaction History
| TLSI | ▼ Sell | Open Market | 273 | $1K | 3/16/2026 | View on chart |
| TLSI | ▼ Sell | Open Market | 1,772 | $7K | 3/12/2026 | View on chart |
| TLSI | ▼ Sell | Open Market | 1,162 | $5K | 3/11/2026 | View on chart |
| TLSI | ▲ Buy | Grant | 50,000 | $0 | 11/24/2025 | View on chart |
| TLSI | ▼ Sell | Open Market | 4,764 | $25K | 5/19/2025 | View on chart |
| TLSI | ▲ Buy | Grant | 24,131 | $125K | 5/19/2025 | View on chart |
| TLSI | ▲ Buy | Grant | 5,272 | $0 | 2/18/2025 | View on chart |
| TLSI | ▲ Buy | Grant | 10,625 | $0 | 1/27/2025 | View on chart |
| TLSI | ▲ Buy | Grant | 17,500 | $0 | 2/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TriSalus Stock Rises After FDA Clears TriNav Advance
TriSalus Life Sciences shares climbed 15.6% following FDA clearance for its TriNav Advance product. This regulatory approval marks a significant milestone for the company's pipeline. The stock is currently testing key support levels after the recent price movement.
TriSalus Stock Rises After FDA Clears TriNav Advance. TriSalus Life Sciences shares climbed 15.6% following FDA clearance for its TriNav Advance product. This regulatory approval marks a significant milestone for the company's pipeline. The stock is currently testing key support levels after the recent price movement.